Comparison between DCF (docetaxel, cisplatin and 5-fluorouracil) and modified EOX (epirubicin, oxaliplatin and capecitabine) as palliative first-line chemotherapy for adenocarcinoma of the upper gastrointestinal tract

Anticancer Research

Volumn 33, Issue 8, 2013, Pages 3455-3460

  Ilhan Mutlu, Aysegul ^a   Preusser, Matthias ^a   Schoppmann, Sebastian F ^a,b   Asari, Reza ^a,b   Ba Ssalamah, Ahmed ^a,b   Schwameis, Katrin ^a,b   Pluschnig, Ursula ^a   Birner, Peter ^a   Puspok, Andreas ^a,b   Zacherl, Johannes ^b   Hejna, Michael ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Division of Gastroenterology and Hepatology   (Austria)

Author keywords

5 fluorouracil; Adenocarcinoma; Capecitabine; Cisplatin; Docetaxel; Epirubicin; G CSF; Gastroesophageal cancer; Oxaliplatin

Indexed keywords

CAPECITABINE; CISPLATIN; DOCETAXEL; EPIRUBICIN; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; OXALIPLATIN;

ABDOMINAL PAIN; ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CHEMORADIOTHERAPY; CLINICAL ARTICLE; COMPARATIVE STUDY; CONSTIPATION; CONTINUOUS INFUSION; DIARRHEA; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL CARCINOMA; HAND FOOT SYNDROME; HEART MUSCLE ISCHEMIA; HUMAN; HYPOTENSION; LUNG EMBOLISM; MALE; NEUROPATHY; NEUTROPENIA; ORAL MUCOSITIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; UPPER GASTROINTESTINAL TRACT; VENOUS THROMBOEMBOLISM; VOMITING;

5-FLUOROURACIL; ADENOCARCINOMA; CAPECITABINE; CISPLATIN; DOCETAXEL; EPIRUBICIN; G-CSF; GASTROESOPHAGEAL CANCER; OXALIPLATIN;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DEOXYCYTIDINE; EPIRUBICIN; FEMALE; FLUOROURACIL; GASTROINTESTINAL NEOPLASMS; HUMANS; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; PALLIATIVE CARE; RETROSPECTIVE STUDIES; TAXOIDS; TREATMENT OUTCOME; UPPER GASTROINTESTINAL TRACT;

EID: 84883265876     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Bertuccio P, Chatenoud L, Levi F, Proud D, Ferlay J, Negri E, Malvezzi M and La Vecchia C: Recent Pattern in gastric cancer: A global overview. Int J Cancer 125: 666-673, 2009.
2. Wagner AD, Groethe W, Haerting J, Kleber G, Grothey A and Fleig WE: Chemotherapy in advanced gastric cancer: A systematic review and meta-analysis based on aggregate data. J Clin Oncol 24: 2903-2909, 2006.
3. Murad AM, Santiago FF and Petrioianu A: Modified therapy with 5-fluorouracil, doxorubicin and methotrexate in advanced gastric cancer. Cancer 72: 37-41, 1993.
4. Pyrhonen S, Kuitunen T, Nyandoto P and Kouri M: Randomized comparison of fluorouracil, epirubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with nonresectable gastric cancer. Br J Cancer 71: 587-591, 1995.
5. Glimelius B, Ekstrom K, Hoffman K, Graf W, Sjoden PO, Haglund U, Svensson C, Enander LK, Linne T, Sellstrom H and Heuman R: Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 8: 163-168, 1997.
6. Wohrer SS, Raderer M and Hejna M: Palliative chemotherapy for advanced gastric cancer. Ann Oncol 15: 1585-1595, 2004.
7. Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, Risse ML and Ajani J: A Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first line treatment for advanced gastric cancer: A Report of the V325 study group. J Clin Oncol 24: 4991-4997, 2006.
8. Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, Oates J, Norman AR and Upper Gastrointestinal Clinical Studies Group of the National Cancer Research Institute of the United Kingdom: Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 358: 36-46, 2008.
9. Bojic M, Pluschnig U, Zacherl J, Thallinger CM, Ba-Ssalamah A, Maresch J, Datler P, Schoppmann SF and Hejna M: Docetaxel, cisplatin and 5-fluorouracil plus granulocyte colonystimulating factor prophylaxis in patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction: Experience at the Medical University of Vienna. Anticancer Res 31: 2379-2382, 2011.
10. Pluschnig U, Schoppmann SF, Preusser M, Datler P, Asari R, Ba-Ssalamah A, Schwameis K, Birner P, Zacherl J and Hejna M: Modified EOX (Epirubicin, Oxaliplatin and Capecitabine) as palliative first-line chemotherapy for gastroesophageal adenocarcinoma. Anticancer Res 33(3): 1035-1039, 2013.
11. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Ruschoff J, Kang YK; ToGA Trial Investigators. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-esophageal junction cancer (ToGA): a phase 3, open-label, randomized controlled trial. Lancet 376: 687-697, 2010.
12. US Department of Health and Human Services; National Institutes of Health; National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE). Version 4.03: NIH Publication No. 09-5410, 2010.
13. Miller AB, Hoogstraten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer 47: 207-214, 1981.